CSI Market
Sign In | Register

Effector Therapeutics Inc (EFTR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EFTR Annual Cash Flow →
The data below summarizes Effector Therapeutics Inc's cash flow activity from Mar 31 2023 to Mar 31 2024, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-8.83
Depreciation & amortization0.03
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.00
Share-based Compensation1.01
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Transaction Costs Allocated To Warrant Liabilities-
Fair Value Adjustment Of Earn Out Liability-
Increase Decrease In Right Of Use Assets And Lease Liabilities Net-
Investment Income Net Amortization Of Discount And Premium-0.06
Other Expense Related To Equity Purchase Agreement0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.72
Increase (Decrease) in Accrued Liabilities0.88
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other0.27
Other Working Capital0.05
Other Noncash Expense0.09
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-7.28
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds-6.32
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-6.32
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.56
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments To Repayment Of Term Loans-
Proceeds From Business Combination Transaction Net Of Offering Costs Paid-
Proceeds From Issuance Of Common Stock Net Of Issuance Cost14.79
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities14.23
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.28
Total Cash Flow0.63
4 historic quarters locked

Sign in to unlock the full Effector Therapeutics Inc cash flow history.

Sign In Create Free Account

About Effector Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-056859

Figures are derived from filed reports and may be restated. Historical data is subject to revision.